About

At GenEdit, we aim to overcome the existing limitations in genetic medicine so we can positively impact the lives of as many people as possible.

Our Vision

Our co-founders Kunwoo Lee, Ph.D., Hyo Min Park, Ph.D., and Niren Murthy, Ph.D., worked closely with Nobel Laureate Jennifer Doudna, Ph.D., (Chemistry, 2020) at UC Berkeley and recognized that identifying the right delivery strategy was the critical step in realizing the potential of CRISPR/Cas9 and other genetic medicines.

GenEdit’s mission is to discover and develop innovative genetic medicines with targeted in vivo delivery. With our team’s collective expertise, we are currently advancing novel therapies and realizing a new era of genetic medicine: one in which we can edit out disease and rewrite patient health.

About

Our Vision

Leadership

Romuald Corbau, Ph.D.

Timothy Fong, Ph.D.

Kunwoo Lee, Ph.D.

Hyo Min Park, Ph.D.

Barbara Leyman, Ph.D.

Derek Sloan, M.D.

Board of Directors

Jiwoong Chun, RPh, MSc

June Lee, M.D.

Kunwoo Lee, Ph.D.

Hyo Min Park, Ph.D.

David Schaffer, Ph.D.

Josephine Chen

HoChan Lee

Thomas Marron, Ph.D.

Advisors

George Church, Ph.D.

Jong-Min Lee, Ph.D.

Matthew Rabinowitz, Ph.D.

Jun Yoon

Jennifer Cygan, Ph.D.

Aaron Mishel

Investors